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not exceed grade 3. As long-term adverse events, liver ab-
scesses, gastroduodenal ulceration, cholestasis and cholan-
gitis, ascites and spleen infarction were observed.  Conclu-
sion:  90 Y radioembolization is able to induce an encouraging 
local response rate of liver metastases of pancreatic cancer 
patients. Most short-term toxicities are manageable; how-
ever, patients should be followed up carefully for severe 
long-term toxicities.  © 2013 S. Karger AG, Basel 
 Introduction 
 Patients with metastatic pancreatic cancer still have 
limited treatment options and outcome is poor. Gem-
citabine remains a backbone in the standard of care for 
these patients and is able to induce a median overall sur-
vival (OS) of about 5–7 months  [1] . Erlotinib as a single 
agent received European Medicine Agency approval for 
the treatment of metastatic disease in combination with 
gemcitabine based on a modest improvement in median 
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 Abstract 
 Objective: To analyze the clinical efficacy of  90 Y radioembo-
lization in liver metastases from pancreatic cancer, to de-
scribe treatment toxicities and to identify biomarkers as pre-
dictors of outcome.  Methods: Data from 19 pancreatic can-
cer patients (9 females/10 males) who had received  90 Y 
radioembolization for metastatic liver disease between 
06/2004 and 01/2011 were analyzed retrospectively.  Re-
sults: The median age at  90 Y radioembolization was 63 years 
(range 43–77). In 16 patients, previous palliative gem-
citabine-based chemotherapy was given for metastatic dis-
ease. Objective response in the liver after  90 Y radioemboliza-
tion was 47%. Median local progression-free survival in the 
liver was 3.4 months (range 0.9–45.0). Median overall sur-
vival (OS) was 9.0 months (range 0.9–53.0) and 1-year sur-
vival was 24%. Cox regression models for baseline biomark-
ers at  90 Y radioembolization revealed correlations of in-
creased carbohydrate antigen 19-9 (p = 0.02) and C-reactive 
protein (p = 0.03) with shorter OS. Short-term adverse events 
(nausea, vomiting, fatigue, fever and abdominal pain) did 
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OS of 0.4 months  [2] . The promising data of the recently 
introduced FOLFIRINOX combination chemotherapy 
regimen showed a median OS of about 11 months; how-
ever, novel active treatment options are still needed for 
this patient population  [3] .
 An interdisciplinary treatment approach to liver me-
tastases including surgery, chemotherapy, radiation ther-
apy and local therapeutic methods such as radiofrequen-
cy ablation, chemo- and radioembolization has evolved 
as a treatment option for several solid tumor entities. 
 Yttrium-90 radioembolization (or selective internal ra-
diation therapy, SIRT) has evolved as a feasible liver-di-
rected therapy in primary liver cancer  [4] and hepatic me-
tastases from colorectal cancer  [5] , neuroendocrine tu-
mors  [6–8] , cholangiocarcinoma  [9, 10] , breast cancer 
 [11, 12] and other tumors  [13] . Only very little experience 
exists with  90 Y radioembolization for liver metastases of 
pancreatic cancer patients. The published data are limited 
to a few cases picked out of a pooled patient cohort with 
various tumor entities  [13–15] . In this article, we report 
on 19 patients with pancreatic cancer treated with  90 Y ra-
dioembolization for liver metastases. It is the first analysis 
that focuses on metastatic pancreatic cancer patients who 
underwent  90 Y radioembolization as a salvage therapy. 
Systemic pretreatment for pancreatic cancer varied ac-
cording to tumor stage at first diagnosis and the physi-
cian in charge before admission to our center for  90 Y ra-
dioembolization. However, most of the patients had pre-
viously received a standard palliative gemcitabine-based 
regimen.
 Therefore, the aim of the present retrospective single-
center study was to analyze the efficacy and safety of liver-
directed treatment with SIRT in patients with liver metas-
tases from pancreatic cancer. Response rates, survival 
data and side effects in this patient cohort were evaluated. 
Furthermore, clinical characteristics, radiological find-
ings and laboratory tests were examined for prognostic or 
predictive values influencing response and survival.
 Materials and Methods 
 Patient Selection 
 The current analysis was a retrospective cohort study of 19 pa-
tients with histologically proven exocrine pancreatic cancer and 
liver metastases who underwent  90 Y radioembolization between 
June 2004 and January 2011 at our university center.
 All patients fulfilled the inclusion criteria for  90 Y radioemboli-
zation  [16] : (1) age >18 years; (2) signed informed consent; (3) 
chemotherapy-refractory pancreatic cancer with liver metastases; 
patients with limited extrahepatic disease were not excluded if the 
hepatic metastases were assessed to be the predominant and pre-
sumably life-limiting factor and the extrahepatic lesions continued 
to be stable over the disease course; (4) preserved liver function 
defined by a serum bilirubin-level  ≤ 2.0 mg/dl and the absence of 
ascites; (5) ECOG performance status 0–2, and (6) estimated life 
expectancy >3 months.
 Patients were excluded if they had (1) signs of liver failure, e.g. 
bilirubin-level >2.0 mg/dl or ascites; (2) complete portal vein oc-
clusion, and (3) evidence of excessive hepatopulmonary shunting 
(>20% in  99m Tc macro-aggregated albumin scan) or angiographi-
cally demonstrable and non-occludable gastrointestinal shunting 
 [17] .
 Irrespective of prior treatment,  90 Y radioembolization was ad-
ministered to all 19 patients as a salvage therapy as liver metastases 
were considered to be the life-limiting factor for the patients. The 
indication and the time point for  90 Y radioembolization were de-
termined by the patient’s oncologist in consultation with an inter-
ventional radiologist and an expert from the Department of Nu-
clear Medicine.
 Pretherapeutic Examinations 
 Before SIRT, all patients underwent imaging examinations 
with whole-body FDG-PET/CT scan and contrast-enhanced MRI 
of the liver to assess the extent of metastatic liver infiltration and 
the presence of extrahepatic disease. For laboratory testing, C-re-
active protein (CRP), lactate dehydrogenase (LDH) and the serum 
tumor markers carbohydrate antigen (CA) 19-9 and carcinoem-
bryonic antigen (CEA) were determined.
 If the patients qualified for  90 Y radioembolization up to this 
point, they received a mapping angiography with visceral catheter-
ization to evaluate their vascular anatomy, the presence of aberrant 
gastrointestinal vessels and the magnitude of hepatopulmonary 
shunting. Therefore, approximately 100 MBq of  99m Tc-macro-ag-
gregated albumin were administered to the left and right hepatic 
arteries in order to estimate the shunt fraction of  90 Y micro-
spheres to the lung vasculature. Prophylactic coil embolization of 
the gastroduodenal artery was performed in all patients (except for 
those after Whipple surgery); embolization of the right gastric and 
other extrahepatic arteries was only performed if it was deemed 
necessary by the interventional radiologist. 
 Radioembolization Technique 
 Resin microspheres (SIR spheres ® , Sirtex Medical Limited, 
Sydney, N.S.W., Australia) labeled with the radioactive isotope 
( 90 Y) were selectively delivered to the tumor-supplying vessels. Re-
garding the detailed technical approach, we refer to the just previ-
ously published standards of practice in transarterial radioembo-
lization  [18] . In our patient cohort, 1.0–2.5 GBq were applied in a 
single administration of microspheres. The body surface area 
method was used to determine the dosage  [19] . Since pancreatic 
cancer patients have an increased risk for ascending cholangitis 
(particularly after Whipple surgery and loss of the papilla func-
tion), all patients received peri-interventional antimicrobial pro-
phylaxis with intravenous ciprofloxacin 200 mg on days 1 and 2 
and oral ciprofloxacin 500 mg on day 3.
 Response and Safety Assessment 
 The first follow-up visit was scheduled 3 months after  90 Y ra-
dioembolization and included physical examination, laboratory 
tests (tumor markers, CRP and LDH), FDG-PET/CT and MRI of 




















   
   
   
   
   
   
   
   
   
   
   


























RECIST criteria (version 1.0) on the MRI and CT scans  [20] . Met-
abolic response was assessed by FDG-PET. The maximum stan-
dardized uptake value was used for PET-based assessment of met-
abolic response and patients with a decline >30% were judged as 
responders  [21] . Further follow-up visits including the above-
mentioned examinations were scheduled every 3 months in survi-
vors. All adverse effects were graded using Common Terminology 
Criteria for Adverse Events (CTC-AE) developed by the National 
Cancer Institute (version 4.0).
 Statistical Analysis 
 Data were summarized by adequate measures of location and 
spread for continuous variables and by proportions for discrete 
variables, e.g. response rates. Survival probabilities for OS and (lo-
cal and systemic) progression-free survival (PFS) were assessed by 
the Kaplan-Meier method. All time-to-event data were calculated 
starting from the day of SIRT until the day of documented disease 
progression or death (or in case of censoring the date of last contact 
with the patient). Univariate Cox proportional hazard models 
were used to explore the impact of independent variables on OS 
and PFS. Tumor and serum markers are considered as continuous 
covariates so that there is no loss of information due to dichotomi-
zation. For such a model, the hazard ratio (HR), its 95% confidence 
interval (CI) and the (two-sided) p value resulting from the Wald 
test are reported. Due to the large number of tests performed, p 
values are reported rather than tests performed with adjustment 
for multiple testing at the 0.05 level of statistical significance. All 
statistical analyses were conducted with the statistical software R 
(version 2.13.2).
 Results 
 Patient and Tumor Characteristics 
 Baseline patient demographics and tumor characteris-
tics are summarized in  table 1 . According to the primary 
tumor location, 15 patients (79.0%) underwent Whipple 
surgery or left-sided pancreatic resection with curative 
intent or for exploratory reason (classified as probably 
resectable on the basis of radiological imaging). Four pa-
tients (21.0%) were classified as nonresectable at the time 
of the fist diagnosis due to radiologically visible metastat-
ic disease. After surgery, 9 patients (47.4%) received ad-
juvant chemotherapy (1 patient in combination with ra-
diotherapy). One single patient underwent neoadjuvant 
chemoradiotherapy with gemcitabine and cisplatin. For 
metastatic disease, 16 patients (84.2%) were treated with 
palliative chemotherapy: 8 patients (42.1%) with gem-
citabine alone and 6 patients (31.6%) with gemcitabine 
and erlotinib. Two patients (10.5%) received other than 
gemcitabine-based chemotherapeutic regimens or exper-
imental treatments, as specified in the legend of  table 1 . 
Three patients (15.8%) did not receive any previous sys-
temic therapy for metastatic disease before SIRT  [22] . 
 Survival Data and Efficacy 
 Survival data were available in all 19 patients. The me-
dian OS, calculated from the time point of  90 Y radioembo-
lization, was 9.0 months (range 0.9–53.0;  fig.  1 a); the 
1-year survival rate was 24.0%. A total of 15 patients died 
Table 1.  Baseline patient and tumor characteristics, prior surgical 





















































































 • Curative: 8 patients (42.1%), exploratory: 3 patients (15.8%).
b Curative and exploratory: 2 patients (10.5%), respectively.
c Extrahepatic metastasis: bone: 2 patients (10.5%), lung: 1 pa-
tient (5.3%), peritoneal carcinosis: 5 patients (26.3%), spleen and 
lienal vein infiltration: 3 patients (15.8%), lymph nodes: 12 patients 
(63.2%, regional and distant lymph node: 6 patients each, 31.6% 
each). 





















   
   
   
   
   
   
   
   
   
   
   


























during the observation period. Thirteen of the 19 study 
patients were evaluable for objective response assessment 
by imaging (using MRI and FDG-PET/CT according to 
RECIST) after a median follow-up of 2.6 months for the 
first radiologic assessment (range 2.1–4.4;  table 2 a). Five 
patients died before the first follow-up assessment. In 
1 patient, the radiological assessment was omitted due to 
clinical suspicion of cancer progression; the patient died 
1 month later. The local overall response rate in the liver 
was 47% (95% CI: 0.25–0.70). However, new extrahepatic 
tumor manifestations evolved after  90 Y radioembolization 
in several patients ( table  2 ). Further analysis revealed a 
median PFS in the liver (PFS local) of 3.4 months (range 
0.9–45.0) and a median systemic PFS regarding all meta-
static manifestations (PFS systemic) of 2.6 months (range 
0.9–14.8;  table 3 ;  fig. 1 b, c). No stable disease was recorded.
 Three patients showed an outstanding long OS af-
ter  90 Y radioembolization, namely 20, 22 and 53 months. 
Table 2.  Response evaluation of lesions in the liver by RECIST and 
evaluation of extrahepatic metastatic disease after a median fol-
low-up of 2.6 months (range 2.1–4.4)
a Six patients (Nos. 3, 7, 14, 16, 18, 19) were excluded due to death 
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b Summary of response rates: liver and extrahepatic metastases
Response at first 
follow-up (after median 
2.6 months) (n = 13/19)
Response: liver  Response: systemic
















PR = Partial response; SD = stable disease; PD = progressive 
disease.
Table 3.  Median (range) time after 90Y radioembolization and ini-
tial diagnosis: OS and PFS in the liver (local) and at all disease sites 
(systemic)
 Time, months




































































 Fig. 1.  a Kaplan-Meier plots of OS following radioembolization 
with  90 Y resin microspheres in pancreatic cancer patients with liv-
er metastasis.  b ,  c Kaplan-Meier plots of the study cohort after ra-
dioembolization for PFS in the liver ( b ; local) and systemically re-




















   
   
   
   
   
   
   
   
   
   
   


























In 1 of these patients, radiological follow-up investiga-
tions confirmed the disappearance of all hepatic tumor 
manifestations and the patient is currently still doing well 
without evidence of disease. In the 2 other patients,  90 Y 
radioembolization led to a long-standing reduction in tu-
mor growth and metabolism before local tumor progres-
sion and distant recurrence.
 Survival and Response by Baseline Characteristics – 
Univariate Cox Model 
 Several patient and tumor characteristics, and radio-
logical and laboratory findings were analyzed regarding 
their prognostic value for OS and PFS ( table 4 ). The fol-
lowing variables were included: sex, age, tumor size, tu-
mor grading and metastatic pattern at initial diagnosis 
of pancreatic cancer; age and metastatic pattern at the 
time of  90 Y radioembolization, prior surgery of the pri-
mary cancer and levels of the serum and tumor markers 
CEA, CA 19-9, LDH and CRP. Univariate Cox analysis 
revealed a significant correlation of elevated baseline 
CA 19-9 (p = 0.02; HR 1.40, 95% CI: 1.06–1.84) and CRP 
(p = 0.03; HR 1.71, 95% CI: 1.07–2.76) with shorter OS 
after  90 Y radioembolization, but no significant correla-
tion for pretreatment CEA (p = 0.12; HR 1.32, 95% CI: 
0.93–1.88) and LDH levels (p = 0.95; HR 1.06, 95% CI: 
0.21–5.28 ). Patients with metastasis limited to the liver 
showed a longer OS compared to patients with liver-
predominant metastasis (p = 0.07; HR 2.9, 95% CI: 
0.34–0.91). Patients with metastases confined to the liv-
er and no extrahepatic tumor manifestation were cate-
gorized as ‘liver only’. Patients were categorized into the 
‘liver-predominant’ group if hepatic metastasis was as-
sessed as a life-limiting factor requiring treatment by 
the attending physician and extrahepatic metastasis 
were present but tumor burden was low and stable over 
the last months. All other variables seem to have no 
prognostic significance for OS or PFS (local and sys-
temic).
 Acute and Delayed Toxicity  
 Short-term toxicities, including general symptoms 
such as fever, nausea, vomiting, fatigue and abdominal 
pain, occurred frequently within the first 10 days after  90 Y 
radioembolization. They were manageable and reversible 
in all patients and did not exceed CTC-AE grade 3 ( ta-
ble 5 ).
 Long-term toxicities occurred weeks or even months 
after  90 Y radioembolization. 1 patient developed upper 
gastrointestinal bleeding due to gastric ulceration and 
needed subsequent gastrectomy. Histopathological ex-
Table 4.  Univariate Cox proportional hazard modeling: OS and PFS (local and systemic) by patient and tumor characteristics, radio-
logical findings and laboratory values
Variable OS PFS (local)  PFS (systemic)
n HR 95% CI p n HR 95% CI p n HR 95% CI p
Sex 19 0.79 0.275–2.288 0.668 19 1.04 0.412–2.648 0.927 18 1.57 0.583–4.258 0.371
At initial diagnosis
Age 19 1.00 0.932–1.080 0.932 19 1.00 0.939–1.075 0.897 18 1.02 0.953–1.090 0.575
Tumor size (TNM) 19 4.45 0.567–34.84 0.156 19 1.04 0.291–3.722 0.950 18 2.80 0.629–12.50 0.176
Grading 18 1.07 0.369–3.081 0.905 18 0.58 0.196–1.693 0.316 17 1.64 0.580–4.620 0.352
Synchronous metastasis 19 1.34 0.453–3.986 0.595 19 0.92 0.360–2.352 0.862 18 1.60 0.592–4.333 0.353
At radioembolization
Age 19 0.99 0.923–1.065 0.821 19 1.00 0.934–1.067 0.958 18 1.01 0.948–1.081 0.707
Liver-only metastasis 18 2.92 0.343–0.912 0.071 18 1.97 0.719–5.394 0.188 17 2.48 0.849–7.266 0.097
Prior surgery of primary 19 0.59 0.123–2.826 0.508 19 0.35 0.105–1.148 0.083 18 0.51 0.162–1.626 0.257
Tumor and serum markers
CEA 18 1.32 0.934–1.877 0.115 18 1.14 0.830–1.558 0.425 17 1.18 0.881–1.576 0.270
CA 19-9 18 1.40 1.062–1.836 0.017 18 1.17 0.968–1.408 0.105 17 1.11 0.923–1.346 0.261
CRP 19 1.71 1.066–2.757 0.026 19 1.41 0.942–2.104 0.095 18 1.39 0.974–1.988 0.069
LDH 18 1.06 0.212–5.280 0.945 18 1.12 0.288–4.355 0.870 17 0.87 0.232–3.262 0.835





















   
   
   
   
   
   
   
   
   
   
   


























amination revealed resin microspheres in the gastric 
wall ( fig. 2 ) and thus suggested radiation-induced gas-
tric ulceration, a known serious complication of  90 Y ra-
dioembolization  [23, 24] . Another 2 patients developed 
liver abscesses. One of them was successfully treated 
with intravenous antibiotics after liver puncture and 
bacterial identification, the other patient died in an ex-
ternal hospital due to infection complications (grade 5 
toxicity). In the latter, the suspicion of liver abscesses on 
ultrasound had been expressed by the physician in 
charge before the patient died. One patient developed 
cholangitis due to bile duct stenosis, which was consid-
ered a side effect of  90 Y radioembolization. In 3 patients, 
ascites was detected within the first 3 months of follow-
up, but its extent and cause were not evaluable in detail. 
In 1 patient, an asymptomatic spleen infarction was re-
corded as an incidental finding at the radiological re-
sponse assessment. 
 Five patients died before the first follow-up. Three pa-
tients might have died from complications after  90 Y ra-
dioembolization: 1 patient from liver abscesses (see 
above) and 2 patients from liver failure. In the latter two, 
the detection of severe ascites and a sharp rise in liver en-
zymes gave rise to the suspicion of a potential radiation-
induced liver disease (RILD). RILD is characterized by 
anicteric nonmalignant ascites, hepatomegaly and eleva-
tion of transaminase and bilirubin levels, and occurs in 
about 4% after radioembolization  [19] . It is the most se-
vere toxicity from microspheres. The body surface area 
approach has shown the lowest incidence of RILD. The 
risk of RILD rises with the radiation dose administered, 
but it results from a multifactorial setting and is not sim-
ply correlated to the total radiation dose delivered. How-
ever, there was no possibility to prove this suspicion and 
the observed liver failure also could have been attribut-
able to the underlying tumor progression. In 2 patients, 
no information about cause of death or clinical condition 
after radioembolization was evaluable due to lacking 
medical care.
Table 5.  Procedure- and radiation-related morbidity after 90Y radioembolization (short- and long-term toxicities)
Toxicities  CTC-AE 
all grades grade 1 grade 2 grade 3 grade 4 grade 5

























































































 Fig. 2. Gastric biopsy in macroscopically visible gastric ulceration 
with histopathological evidence of resin microspheres in the gas-




















   
   
   
   
   
   
   
   
   
   
   



























 A considerable amount of promising data has been 
published in the last years regarding the use of radioem-
bolization with  90 Y microspheres for the treatment of pri-
mary liver cancer  [4, 25] or liver metastases from colorec-
tal cancer  [26, 27] , neuroendocrine tumors  [7] and other 
tumors, such as cholangiocellular carcinoma  [28] and 
breast cancer  [11] . Up to now, almost no data exist on the 
use of  90 Y radioembolization in pancreatic cancer pa-
tients, which explains why no comparable data on sur-
vival and response rates, efficacy and toxicity were found 
in the review of the literature. One study was published 
by Cao et al.  [15] , who reported a case series on 7 pancre-
atic cancer patients of whom 3 had reached a partial re-
sponse or stable disease.
 In the current study, we present the largest series of 
pancreatic cancer patients who received  90 Y radioemboli-
zation for metastatic liver disease up to date. Though data 
were analyzed retrospectively, detailed information about 
the patients’ medical history, previous treatment (includ-
ing surgery, chemotherapy, radiotherapy and local treat-
ment methods) as well as follow-up data were available for 
evaluation. In our patient cohort, we observed a median 
OS of 9.0 months after  90 Y radioembolization, which rep-
resents an unexpectedly long OS in metastatic pancreatic 
cancer patients after first-line treatment  [29] . Although 
 90 Y radioembolization is a liver-directed treatment option 
we differentiated local and systemic response evaluation. 
Both the response rate (overall response rate in the liver 
47%) and the local PFS (3.4 months) in our patient cohort 
revealed a high degree of concordance with those of other 
tumor entities  [7, 11, 12] . However, with respect to extra-
hepatic tumor manifestations, systemic tumor response 
evaluation turned out to be significantly worse ( table 2 ).
 Therefore, we investigated clinical, radiological and 
laboratory factors regarding their prognostic and predic-
tive value for response and survival ( table  4 ). Perfor-
mance status, tumor and serum markers, disease burden 
and metastatic pattern have been described to be prog-
nostic and predictive factors for survival in pancreatic 
cancer patients  [30] . Furthermore, kinetics of the tumor 
markers CEA and CA 19-9 as well as the serum parame-
ters CRP and LDH have been closely investigated and re-
ported to have prognostic value for survival after second-
line treatment in advanced pancreatic cancer patients re-
cently  [31] . In the current SIRT study, we identified the 
tumor marker CA 19-9 and the serum marker CRP as 
potential prognostic biomarkers for OS. In addition, pa-
tients with metastases limited to the liver showed a ten-
dency to live longer than patients with extrahepatic dis-
ease. Interestingly, CEA and LDH were not of prognostic 
value for OS.
 Most experience regarding safety and toxicity of  90 Y 
radioembolization can be derived from studies with he-
patocellular carcinoma, colorectal cancer and neuroen-
docrine carcinoma patients  [4, 7, 30] . In general, a differ-
entiation into acute (early or short-term) and chronic 
(delayed or long-term) toxicities is performed. Acute tox-
icities are generally reported as procedure-related events 
and occur 1–14 days after radioembolization  [16] . They 
include general symptoms such as fever, nausea, vomit-
ing, fatigue and abdominal pain, and are often referred to 
as the postembolization syndrome. Delayed toxicities are 
considerable radiation-induced complications occurring 
weeks or months after radioembolization and are fre-
quently caused by unintended deposition of  90 Y micro-
spheres into organs other than the liver. Accordingly, ra-
diation damage results in gastric ulceration  [23, 24] , 
pneumonitis  [32] , cholecystitis  [33] or pancreatitis. The 
occurrence of liver abscesses  [34] or cholangitis due to 
bile duct stenosis  [35] has been described as a possible 
complication of  90 Y radioembolization. RILD remains a 
rare but serious adverse event  [19, 36, 37] .
 Our patient cohort presented with a very low incidence 
of severe acute toxicities (only CTC-AE grades 1 and 2 and 
only 1 patient with fatigue CTC-AE grade 3), which were 
all manageable and completely reversible ( table 5 ). How-
ever, the frequency and severity of observed long-term 
toxicities in our patient population was rather unexpected 
and high. We suspect that long-term toxicities after SIRT 
are not systemically tracked, potentially misinterpreted as 
signs of tumor progression and presumably underestimat-
ed. We also hypothesize that the rate of delayed toxicities 
in pancreatic cancer patients may be higher than in other 
patients receiving  90 Y radioembolization. Especially infec-
tious complications such as liver abscesses might occur 
due to the loss of papilla function after Whipple surgery, 
which our data, however, could not approve at that point.
 Despite limitations of the present study as a retrospec-
tive single-center data analysis in a selected patient cohort 
with different pretreatments and a nonstandardized fol-
low-up, we suggest that  90 Y radioembolization may be a 
reasonable treatment option for hepatic metastases from 
pancreatic cancer. We showed that increased baseline 
levels of CA 19-9 and CRP correlate with shorter OS and 
appear to serve as prognostic factors for survival after  90 Y 
radioembolization. However, further prognostic and pre-
dictive factors need to be identified in order to allow bet-




















   
   
   
   
   
   
   
   
   
   
   


























prognostic factors, the importance of pretreatment, espe-
cially Whipple surgery, as risk factors for morbidity and 
mortality after SIRT remains unclear. In prospectively 
planned studies, pancreatic cancer patients with liver-on-
ly metastases should be selected for radioembolization. 
CA 19-9 and CRP may serve as valuable selection criteria. 
Combination with peri-interventional chemotherapy 
regimens as applied with SIRT in other malignancies 
should be evaluated. Despite well-tolerable short-term 
toxicities, long-term toxicities may be severe and con-
cerning. Therefore, systematic and careful follow-up con-
sultations are needed in order to understand especially 
long-term toxicities in detail. 
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